New! Sign up for our free email newsletter.
Science News
from research organizations

New option for treating prostate cancer

Innovative strategy reduces tumor growth and strengthens the immune system against tumor cells

Date:
November 8, 2024
Source:
Medical University of Vienna
Summary:
Prostate cancer is the second most common cancer in men worldwide. Researchers have investigated a new strategy for the development of treatment options that not only slow tumor growth, but also stimulate the immune system to combat tumor cells.
Share:
FULL STORY

Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of tumour is still responsible for one in eight male cancer deaths in Austria alone. An international research team led by MedUni Vienna has now investigated a new strategy for the development of treatment options that not only slow tumour growth, but also stimulate the immune system to combat tumour cells. The results of the study have just been published in the top journal Molecular Cancer.

The scientific team focused its investigations on the GP130 signalling pathway, which researchers expect to have a major potential in the fight against cancer. The background: the signalling pathway, which is mediated by the protein GP130, plays a central role in cell communication and influences the activity of the transcription factor STAT3, which in turn is associated with the development and spread of tumours. Accordingly, blocking the GP130 signalling pathway is currently seen as a great hope in cancer medicine. Yet the current study proves the opposite: tumour growth can be slowed down not by inhibiting but by activating the GP130 signalling pathway in prostate cells.

New hope, especially for aggressive tumours

To achieve these new findings, the researchers investigated genetically modified mice in which GP130 was specifically activated in the prostate. "This allowed us to directly observe the reduction in tumour growth in the cell," reports Lukas Kenner (Clinical Department of Pathology, MedUni Vienna), who led the study together with Stefan Rose-John (Biochemical Institute, University of Kiel). The results were further backed up by analyses of tissue samples from prostate cancer patients. This showed that high GP130 values correlate with a better survival rate. At the same time, extensive molecular analyses were carried out, including gene expression profiling.

"Our research provides exciting new evidence that the activation of GP130 in prostate cells not only slows tumour growth, but also stimulates the immune system to actively fight the cancer cells," says Lukas Kenner, summarising the significance of the results, which will now be confirmed in further studies. The research work opens up a promising new therapeutic option, particularly for aggressive prostate cancer, which is still difficult to treat.


Story Source:

Materials provided by Medical University of Vienna. Note: Content may be edited for style and length.


Journal Reference:

  1. Christina Sternberg, Martin Raigel, Tanja Limberger, Karolína Trachtová, Michaela Schlederer, Desiree Lindner, Petra Kodajova, Jiaye Yang, Roman Ziegler, Jessica Kalla, Stefan Stoiber, Saptaswa Dey, Daniela Zwolanek, Heidi A. Neubauer, Monika Oberhuber, Torben Redmer, Václav Hejret, Boris Tichy, Martina Tomberger, Nora S. Harbusch, Jan Pencik, Simone Tangermann, Vojtech Bystry, Jenny L. Persson, Gerda Egger, Sarka Pospisilova, Robert Eferl, Peter Wolf, Felix Sternberg, Sandra Högler, Sabine Lagger, Stefan Rose-John, Lukas Kenner. Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment. Molecular Cancer, 2024; 23 (1) DOI: 10.1186/s12943-024-02114-8

Cite This Page:

Medical University of Vienna. "New option for treating prostate cancer." ScienceDaily. ScienceDaily, 8 November 2024. <www.sciencedaily.com/releases/2024/11/241108113714.htm>.
Medical University of Vienna. (2024, November 8). New option for treating prostate cancer. ScienceDaily. Retrieved November 8, 2024 from www.sciencedaily.com/releases/2024/11/241108113714.htm
Medical University of Vienna. "New option for treating prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2024/11/241108113714.htm (accessed November 8, 2024).

Explore More

from ScienceDaily

RELATED STORIES